PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Grifols SA () from 2008 to Jan 17 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Grifols stock (GIKLY) PE ratio as of Jan 17 2021 is 24.13. More Details

Grifols PE Ratio (TTM) Chart

EMBED

Grifols PE Ratio (TTM) Historical Data

Total 1244
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Grifols PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-01-1726.2 2020-11-1125.2
2021-01-1526.2 2020-11-1025.2
2021-01-1426.2 2020-11-0925.2
2021-01-1325.8 2020-11-0625.2
2021-01-1225.8 2020-11-0525.2
2021-01-1125.8 2020-11-0425.2
2021-01-0825.8 2020-11-0325.2
2021-01-0727.2 2020-11-0225.2
2021-01-0627.2 2020-10-3025.2
2021-01-0527.2 2020-10-2925.2
2021-01-0427.2 2020-10-2825.2
2020-12-3127.2 2020-10-2727.3
2020-12-3027.2 2020-10-2627.3
2020-12-2927.2 2020-10-2327.3
2020-12-2827.2 2020-10-2227.3
2020-12-2427.2 2020-10-2127.3
2020-12-2327.2 2020-10-2027.3
2020-12-2227.2 2020-10-1927.3
2020-12-2127.2 2020-10-1627.5
2020-12-1827.2 2020-10-1527.5
2020-12-1726.0 2020-10-1424.7
2020-12-1626.0 2020-10-1324.7
2020-12-1526.0 2020-10-1224.7
2020-12-1426.0 2020-10-0924.7
2020-12-1126.0 2020-10-0824.7
2020-12-1025.3 2020-10-0724.7
2020-12-0925.3 2020-10-0624.7
2020-12-0825.3 2020-10-0524.7
2020-12-0725.3 2020-10-0224.7
2020-12-0425.5 2020-10-0124.7
2020-12-0325.5 2020-09-3024.7
2020-12-0225.5 2020-09-2924.7
2020-12-0125.5 2020-09-2824.7
2020-11-3025.5 2020-09-2531.3
2020-11-2725.5 2020-09-2431.3
2020-11-2525.5 2020-09-2331.3
2020-11-2427.2 2020-09-2231.3
2020-11-2327.2 2020-09-2131.3
2020-11-2027.2 2020-09-1831.3
2020-11-1927.2 2020-09-1731.3
2020-11-1827.2 2020-09-1631.3
2020-11-1727.2 2020-09-1531.3
2020-11-1627.2 2020-09-1431.3
2020-11-1327.2 2020-09-1131.3
2020-11-1225.2 2020-09-1031.3

Grifols PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Drug Manufacturers » NAICS : 325412
Address Avinguda de la Generalitat, 152-158, Parque empresarial Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.